Phaseline

Companies › SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany: clinical trials, targets and expected readouts

3 active drug programs in 14 registered trials: 7 Phase 1, 6 Phase 2, 1 Phase 4; Oncology, Gastroenterology, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nirogacestat
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 4Desmoid TumorMay 2027
Mirdametinib (PD-0325901)
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Plexiform Neurofibroma; Healthy; Slow-Flow Vascular Malformation; Advanced Unresectable Melanoma …Dec 2028
SW-682
Hippo pathway inhibitor
–Phase 1Advanced Solid TumorJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06997276Mirdametinib (PD-0325901)Phase 1HealthyGastroenterologyOct 2026
NCT05983159Mirdametinib (PD-0325901)Phase 2Slow-Flow Vascular MalformationOtherJan 2027
NCT06251310SW-682Phase 1Advanced Solid TumorOncologyJan 2027
NCT07170644NirogacestatPhase 2Desmoid TumorOncologyMay 2027
NCT07237100Mirdametinib (PD-0325901)Phase 2Advanced Unresectable MelanomaOncologyOct 2027
NCT05937906Mirdametinib (PD-0325901)Phase 1Non-Small Cell Lung CancerOncologyJul 2028
NCT06843967Mirdametinib (PD-0325901)Phase 1Well Differentiated LiposarcomaOncologyAug 2028
NCT03962543Mirdametinib (PD-0325901)Phase 2Plexiform NeurofibromaOncologyDec 2028
NCT07539441Mirdametinib (PD-0325901)Phase 1Central Nervous System TumorsOncologyOct 2029
NCT07061951Mirdametinib (PD-0325901)Phase 2Recurrent Chronic Lymphocytic LeukemiaOncologyFeb 2030
NCT06153173Mirdametinib (PD-0325901)Phase 2Langerhans Cell Histiocytosis (LCH)OncologyMar 2030
NCT06666348Mirdametinib (PD-0325901)Phase 1Pediatric Low-grade GliomaOncologyApr 2030
NCT07176689NirogacestatPhase 4Desmoid TumorOncologyFeb 2031
NCT04923126Mirdametinib (PD-0325901)Phase 1Low-Grade GliomaOncologyJun 2031

Targets

MAP2K1 (1) MAP2K2 (1) APH1A (1) PSENEN (1) APH1B (1) PSEN1 (1) NCSTN (1)

Companies with the same targets

Roche GSK AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma Pasithea Therapeutics Novartis Merck KGaA Verastem Pfizer

Companies built like this

Shanghai Kechow Pharma Hinova Pharmaceuticals Xuanzhu Biopharmaceutical Shanghai Fosun Pharmaceutical Industrial Development Stemline Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.